HAI Book 2020 - Dec 18B

n predicts individual differences in
al older adults

. Castillo1, Divya Channappa1, Nicole Corso1,
adiadwala2, Wanjia Guo4, Carmen Azevedo1,
1, Jacob N. Hall1, Sharon J. Sha1, Carolyn
Frederick Chin1, Anthony D. Wagner1,

umulation in the entorhinal cortex (ERC) and
y normal older adults using novel tau PET ligand 18F-

older adults (ages 60-88 years) enrolled in the
seven had CSF amyloid and phospho-tau data
PET to measure focal tau accumulation in ERC and
nferior cerebellum reference). Seven amyloid+
e also scanned with 18F-PI2620 PET. Episodic memory
ory for word-image pairs (associative d’), and 2)
ceptually similar lure objects (lure discrimination d’).
r in CN compared to amyloid+ patients with cognitive
AB42, but not CSF phospho-tau. In contrast, ERC tau
CSF AB42. HC tau SUVR exhibited a significant
e discrimination d’. In contrast, ERC tau SUVR and
did not explain significant variance in either measure

dial temporal lobe tau in cognitively normal older
lity within this range contributes to individual
h abnormal CSF amyloid. The use of novel ligand 18F-
fer increased sensitivity relative to global (i.e., CSF)
cts of tau pathology on episodic memory in

ormal Aging, Episodic Memory

76

Unschuld, Paul.

P171: Temporo-limbic tau burden, as
correlate of hippocampal volume loss

Jannis Fischer1, Max Ahnen1, Günther Dissertor
Buck2, Sonja Kagerer3,4, Anton Gietl3,4, Christo

1Institute for Particle Physics and Astrophysics, ETH
2Institute of Pharmacology and Toxicology, Universit
Switzerland
3Institute for Regenerative Medicine (IREM), Univers
4Psychiatric University Hospital Zurich (PUK), Zuric
5Data used in preparation of this study were obtained
Initiative (ADNI) database (adni.loni.usc.edu). A com
http://adni.loni.usc.edu/wp-content/uploads/how_to_a
Francisco, CA, US

The positron emission tomography (PET) tracer 18F A
Alzheimer's disease (AD). The current study was aime
18F AV1451 SUVR for hippocampal volume loss ove
levels.

Data were obtained from the Alzheimer's Disease Neu
the current study 102 participants with 18F AV1451 P
Magnetic Resonance Imaging (MRI) scans were inclu
performance levels ranged from normal to severe cogn
14, max. 30). Mean time between first and last MRI w
change over time was obtained by FreeSurfer subcorti
regional 18F AV1451 SUVR with strongest regressio
volume correction was applied.

The average slope of all annual hippocampal volume
effects of AV1451 SUVR on annual hippocampal atro
voxels) located in: 1.) Right Temporal Lobe, Superior
16/2/-32 (T=11.49), -6/16/-16 (T=9.6), -30/0/-34 (T=9
kE=741 voxels, peaks (MNI): 34/16/-38 (T=11.19), 1

Our data demonstrate a strong relationship between te
hippocampal atrophy in old aged adults. Our findings
volume loss in old age and corroborate an association
neurodegenerative brain damage, as reflected by trajec

47

measured by 18F-AV1451, is a
over time

ri1, Werner Lustermann1, Bruno Weber2, Alfred
oph Hock3, Paul Unschuld3,4

Zurich, Zurich, Switzerland
ty of Zurich (UZH) and ETH Zurich, Zurich,

sity of Zurich (UZH), Zurich, Switzerland
ch, Switzerland
d from the Alzheimer’s Disease Neuroimaging
mplete listing of ADNI investigators can be found at:
apply/ADNI_Acknowledgement_List.pdf, San

AV1451 is a valid measure for tau pathology in
ed at characterizing predictive validity of regional
er time, irrespective of present cognitive performance

uroimaging Initiative database (adni.loni.usc.edu). For
PET and at least three longitudinal T1 weighted
uded (mean age: 76.02 +-6.44 years). Cognitive
nitive dysfunction (mean MMSE 27.85, +-2.85, min.
was 1664.1 +-546.5 days. Hippocampal volume, and
ical segmentation. SPM12 was used to determine
on effects for hippocampal atrophy per year. No partial

trajectories was -0.047 (+- 0.056) ml/year. Strongest
ophy resulted for two clusters (extent threshold k=300
r Temporal Gyrus, kE=573 voxels, peaks (MNI): -
9.47); 2.) Left Limbic Lobe, ParaHippocampal Gyrus,
16/4/-30 (T=11.16), 20/-4/-38 (T=11.11).

emporal and limbic lobe AV1451 SUVR, and annual
are consistent with earlier reports on regional brain
n between temporo-limbic tau burden and
ctories of hippocampal atrophy. Moreover, our study

77

supports validity of tau-PET for inferring on progressi
Peak AV-1451 SUVR with strongest effects on annua
Keywords: AV1451, tau, hippocampal atrophy

47

ion of AD pathology at all disease stages.
al hippocampal atrophy trajectories.

78

Ances, Beau

P172: Temporal evaluation for maxim
[18F]Flortaucipir concordance

Julie Wisch1, Brian Gordon1, Suzanne Schindler
Tammie Benzinger1, John Morris1, Beau Ances1

1Washington University, St. Louis, MO, US
Background: Alzheimer’s disease (AD) is characteriz
Clinical trials for AD have historically emphasized am
demonstrated poor efficacy in preventing cognitive ch
Amyloid-Tau(Neurodegeneration) (A-T(N)) framewo
positron emission tomography (PET) tau imaging as a
This analysis aims to identify the time window for wh
concordance and specify the optimal CSF pTau181 thre
Methods: PET for amyloid and tau were obtained for
Disease Research Center (Table 1). CSF pTau181 was
participants. We used two-year bins to calculate the S
(Figure 1) and regional tau as measured by [18F]florta
operating characteristic analysis to identify the optima
window for data collection) associated with tau PET p
Results: The greatest concordance occurs when lumb
imaging in a mixed cohort (R = 0.541) and 6 to 8 year
pathologic change (R = 0.602). CSF pTau181 is a reaso
0.749).
Conclusions: Understanding the temporal relationship
clinical trial outcome development. If a drug targeting
could be evaluated by comparing earlier CSF pTau181
should be taken when classifying individuals as “Tau
and PET measures interchangeably.

47

mum CSF pTau181 –

r1, Shaney Flores1, Aylin Dincer1, Anne Fagan1,

1

zed by mis-aggregation of amyloid and tau proteins.
myloid reduction/prevention, but have generally
hange. Tau is now a therapeutic target of interest. The
ork includes cerebrospinal fluid (CSF) pTau181 and
appropriate measures of tau.
hich CSF pTau181 and tau PET have greatest
eshold for tau positivity.
r 161 participants enrolled at the Knight Alzheimer
assayed (using an Elecsys platform) for these
Spearman correlation of CSF pTau181 with tauopathy
aucipir (Figure 2). Finally, we performed receiver
al CSF pTau181 threshold (and the appropriate time
positivity.
bar puncture is performed 4 to 6 years prior to PET
rs prior to PET in a cohort of individuals with AD
onably good predictor of tau PET positivity (AUC =

p between CSF and PET could be a powerful tool in
g tau can reduce mature tangle development, this

measurements with current tau PET. Further, care
Positive” in the A-T(N) framework and utilizing CSF

79

Keywords: PET, CSF, Alzheimer’s disease, flortaucip
48

pir
80

Wolters, Emma

P173: [18F]flortaucipir PET is more c
than CSF p-tau in Alzheimer’s disease

Emma Wolters1,2, Rik Ossenkoppele2,3, Sander V
Timmers1,2, Denise Visser1, Hayel Tuncel1, San
Boellaard1, Wiesje van der Flier2,4, Charlotte Te

1Department of Radiology & Nuclear Medicine, Amst
Amsterdam UMC, Amsterdam, The Netherlands
2Alzheimer Center Amsterdam,, Department of Neuro
Amsterdam, Amsterdam UMC, Amsterdam, The Nethe
3Clinical Memory Research Unit, Lund University, Lu
4Department of Epidemiology and Biostatistics, Vrije
Amsterdam, The Netherlands
5Neurochemistry Laboratory, Department of Clinical
UMC, Amsterdam, The Netherlands

Background: In vivo Alzheimer’s disease (AD) biom
(CSF) phosphorylated tau (p-tau) and [18F]flortaucipir
CSF p-tau with [18F]flortaucipir PET, and ii) associat
atrophy.

Methods: We included 78 amyloid positive cognitive
(n=45)) and 25 cognitively normal subjects (40% amy
PET scans were acquired to generate binding potentia
We obtained regional BPND from regions-of-interest (
was assessed using MMSE and composite scores of fo
using the using gray matter volumes covering the maj
models to investigate associations between CSF p-tau
cognition or atrophy (model 1). We then assessed the
cognition or atrophy by simultaneously adding the oth
were adjusted for age, sex, time lag between assessme
volume (atrophy only).

Results: Higher [18F]flortaucipir BPND across all ROIs
standardized betas, sβ =0.43-0.46, all p<0.01, figure 1
entered simultaneously, [18F]flortaucipir BPND (range
associated with multiple cognitive domains and atroph
associated with MMSE (sβ = -0.21, p<0.05), particula

Conclusion: [18F]flortaucipir BPND showed stronger a
than CSF p-tau. As such, tau PET may more accuratel

48

closely associated with disease severity
e

Verfaillie1, Emma Coomans1, Tessa
ndeep Golla1, Albert Windhorst1, Ronald
eunissen5, Philip Scheltens2, Bart van Berckel1

terdam Neuroscience, Vrije Universiteit Amsterdam,

ology, Amsterdam Neuroscience, Vrije Universiteit
erlands
und, Sweden
Universiteit Amsterdam, Amsterdam UMC,

Chemistry, Vrije Universiteit Amsterdam, Amsterdam

markers for tau pathology are cerebrospinal fluid
r PET. Our aim was to assess i) associations between
tions of both tau biomarkers with cognition and

ely impaired patients (MCI (n=8) and AD dementia
yloid-positive). Dynamic 130 minute [18F]flortaucipir
al (BPND) images using receptor parametric mapping.
(ROIs) closely aligning to the Braak stages. Cognition
our cognitive domains, while atrophy was measured
jor brain lobes. We performed linear regression
u and tau PET and between CSF p-tau, tau PET and
independent effects of CSF p-tau and tau PET on
her tau biomarker as a predictor (model 2). Models
ents, education (cognition only) and total intracranial

Is were associated with higher CSF p-tau (range of
1). When [18F]flortaucipir BPND and CSF p-tau were
e sβ = -0.20 - -0.57, all p<0.05) was strongly
hy regions, while CSF p-tau was exclusively
arly for MCI/AD patients (table-1, 2).

associations with cognition and neurodegeneration
ly reflect disease severity in AD than CSF p-tau.

81

48

82

48

83

Keywords: Tau, CSF, PET, cognition, atrophy
48

84

Ziontz, Jacob

P174: Associations of tau pathology an
retrospective cognitive change among

Andrea Shafer1, Murat Bilgel1, Jacob Ziontz1,2,

1Laboratory of Behavioral Neuroscience, National Ins
2Helen Wills Neuroscience Institute, University of Cal
3Department of Radiology and Radiological Science,
Baltimore, MD, US
Introduction: Tau pathology in cognitively normal (C
hyper-connectivity. Tau and functional connectivity a
interact to influence cognitive change in CN individua
Methods: We used data for 59 individuals (mean age
Longitudinal Study of Aging to investigate the cross-s
(measured as FTP SUVR) and intra-regional connecti
default mode network (DMN) and DMN subregions im
ability (precuneus). We then investigated the associati
retrospective rates of change in memory (California V
delayed recall, n=393 longitudinal observations) and v
repeated analyses using parahippocampal instead of h
spillover.
Results: Controlling for age, sex, PiB status, and fMR
with greater hippocampal connectivity [b=0.63, p=0.0
and PiB status, higher hippocampal tau at last visit wa
[b=-0.086, p=0.0001], while higher hippocampal conn
decline in memory over time [b=0.267, p=0.001] (Fig
steeper decline in visuospatial ability [b=-0.165, p=0.0
individuals with more hippocampal tau (time*hippoca
0.872, p=0.005]) (Figure 2). All results were replicate

48

nd functional connectivity with
cognitively normal older adults

Dean Wong3, Susan Resnick1

stitute on Aging, Baltimore, MD, US
lifornia Berkeley, Berkeley, CA, US
Johns Hopkins University School of Medicine,

CN) older adults is associated with
are individually related to cognition, but how they
als remains unclear.
e at tau PET 77.9, SD 8.6) in the Baltimore
sectional association between hippocampal tau
ivity (measured using resting state fMRI) for the
mportant for memory (hippocampus) and visuospatial
ions of hippocampal tau and connectivity with
Verbal Learning Test composite of immediate and
visuospatial ability (Card Rotation Test, n=376). We
hippocampal tau due to potential choroid plexus signal

RI motion, higher hippocampal tau was associated
049]. Longitudinally, after controlling for age, sex,
as related to steeper retrospective memory decline
nectivity at last visit was related to a less severe
gure 1). Higher precuneus connectivity was linked to
043], and this association was exacerbated in
ampal tau*precuneus connectivity interaction: [b=-
ed in models with parahippocampal tau.

85

Discussion: Our results show regionally dependent re
protein accumulation, connectivity, and cognition. Co
related to intra-regional functional connectivity. Exten
modified by hippocampal tau and intra-regional conne
Keywords: FTP, resting state, fMRI, memory, visuosp

48

elationships between PET markers of pathological
onsistent with previous findings, we show tau is
nding previous work, we show cognitive change is
ectivity.
patial

86

Friday, January 17, 2020 - 10:00am - 11:00am

SESSION VIIB: TAU II

Friday, Janu

10:00 AM SESSION VIIB:
TAU II

10:00 AM Critical threshold of elevated amyloid
associated with rapid tau
accumulation: a ca-tau-strophe in the
making

10:15 AM The Meaning of Tau Positivity with
Respect to Clinical Progression

Longitudinal tau PET changes in
10:30 AM cognitively unimpaired persons with

different β-amyloid levels

Defining a tau positive flortaucipir
10:45 AM PET signal relative to AD

neuropathology

11:00 AM Discussion (VII A and VII B)

48

uary 17, 2020

CHAIRS:
Clifford Jack, MD, Mayo Clinic
Reisa Sperling, MD, Brigham and Women's Hospital
Victor Villemagne, MD, Austin Health
Keith Johnson, MD, Massachusetts General
Hospital
Michael Devous, PhD, Avid Pharmaceuticals
David Knopman, MD, Mayo Clinic
Michael Pontecorvo, PhD, Avid Pharmaceuticals

87

Johnson, Keith

Critical threshold of elevated amyloid
accumulation: a ca-tau-strophe in the

Keith Johnson1, Heidi Jacobs1, Bernard Hanseeu
Aaron Schultz1, Kathryn Papp1,3, Julie Price1, D

1Massachusetts General Hospital / Harvard Medical S
2Cliniques Universitaires Saint-Luc, Brussels, Belgium
3Brigham and Women’s Hospital / Harvard Medical S

Introduction: Amyloid-beta (aβ) and PHF tau protein
spatiotemporal sequence by which tau accumulation i
seemingly benign medial temporal lobe tauopathy into
Therapeutic strategies to interrupt the disease process
critical points in the interacting trajectories of aβ and t
Methods: We characterized concurrent change in aβ a
age=75.18 years, SD=6.96 years; 78 females; n=123 w
PiB DVR and Flortaucipir (FTP, composite of entorhi
PET imaging of up to four time points (299 observatio
months] was included (Figure 1). Subject-specific slop
regressions, covarying for baseline PiB and baseline a
were assessed in a model-free manner using Generaliz

Results: We found a positive relationship between Pi
scale bar SUVR, t=3.72, p<0.001, adjusted for baselin
a critical baseline aβ-level was reached (approximate
interaction baseline PiB by PIB change t=-1.98, p=0.0
associated with faster rates of both PiB and FTP accum
tau accumulation coincided with cognitive decline, wi
mild cognitive impairment (Figure 3).

Conclusion: Reaching a critical threshold of amyloid
accumulation of both Aβ and tau in a subset of clinica
imminent clinical decline.

48

d associated with rapid tau
making

uw1,2, Justin Sanchez1, John Alex Becker1,
Dorene Rentz1,3, Reisa Sperling1,3

School, Boston, MA, US
m
School, Boston, MA, US

nopathies define Alzheimer’s disease and follow a
is rapidly accelerated with aβ, transforming a
o a cascade of injurious events that leads to dementia.
may be more advantageously applied at specific
tau.
and tau in HABS participants (N=131 with mean
with CDR=0 and n=8 with CDR>= 0.5) using cortical
inal and inferior temporal cortex) SUVr. Longitudinal
ons, median 29.65 months [IQR, 22.36 – 39.53
pes in FTP and PiB were associated using linear
age. Nonlinear relationships between both biomarkers
zed Additive Models (GAM).
iB change (y-axis) and FTP change (Figure 1 & 2
ne PiB), such that FTP accumulation accelerated once
PiB DVR= 1.1 - 1.2, with quadratic effect of the
050). Higher levels of baseline PiB (x-axis) were
mulation (GAM, p<0.005; Figure 2). Rapid Aβ and
ith the majority of these participants progressing to

dosis appears necessary to precipitate rapid
ally normal older individuals and is associated with

88

48

89

49

90

Keywords: Amyloid, tau, cognitive decline, trajectorie
49

es, PET
91

Devous, Michael

The meaning of tau positivity with res

Michael Devous1, Adam Fleisher1, Michael Pon
Galante1, Sudeepti Southekal1, Anupa Arora1, M

1Avid Radiopharmaceuticals, Philadelphia, PA, US

Objective: Identify characteristics of flortaucipir scan
Methods: The relationship of baseline flortaucipir to
pivotal registration trials, A05C (159 MCI/AD; MMS
30), and by studies A05E (149 MCI/AD) and the tau a
and PX01 evaluated relationships between flortaucipir
and functional deterioration. Visual reads were dicho
parietal uptake, or frontal uptake with posterolateral te
of an Advanced tau AD pattern.
Quantitative analyses used a weighted neocortical VO
incorporating mesial and inferior temporal regions (Fi
mean+2.5*SD of young controls. Multivariate stepwi
from the pooled longitudinal sample, with CDR-SB, M
dependent variables and predefined independent risk f
Results: The primary aim for the two pivotal trials (C
but met in PX01 (p=.0313). All progression endpoint
elevated risk for Advanced vs. non-Advanced pattern
significant (p< 0.0001) for each test in multivariate m
MUBADA below threshold (Figure 1B) showed inter
cortical thickness, and MMSE compared to subjects b
(most progression) on both measures.
Conclusions: Visual read patterns and quantitative m
pooled analyses. Et SUVr was associated with progre
tau positive subjects for MMSE.

49

spect to clinical progression

ntecorvo1, Ming Lu1, Vikas Kotari1, Nicholas
Mark Mintun1

ns associated with significant risk of progression.
18-month cognitive decline was investigated in two
SE 20-27) and PX01 (205 Aβ+ MCI/AD, MMSE 20-
addendum of LZAX (TZAX; 204 Aβ+ AD). A05C
r visual image reads and risk of subjects’ cognitive
otomized into: an Advanced tau AD pattern (increased
emporal, parietal, or occipital uptake) or no evidence

OI (MUBADA) and an “early tau” VOI (Eτ)
igure 1A). SUVr positivity was set as ≥
ise regression analyses were conducted using subjects
MMSE, ADAS, and FAQ change from baseline as
factors (Table 1B).
CDR-SB ≥1-pt change) was missed in A05C (p=.067)
ts were significant in pooled analyses showing
subjects (Table 1A, Figure 2). MUBADA SUVr was
models (Table 1B). Subjects with Et SUVr above but
rmediate progression in MUBADA and Et SUVr,
below threshold (least progression) or above threshold

measures were associated with 18 month progression in
ession midway between tau negative and MUBADA

92

49

93

49

94

Keywords: Progression, Tau, Flortaucipir, Positive S
49

Scan
95

Knopman, David

Longitudinal tau PET changes in cogn
different β-amyloid levels

David Knopman1, Emily Lundt1, Terry Thernea
Albertson1, David Jones1, Jon Graff-Radford1, R

1Mayo Clinic, Rochester, MN, US
Tau PET imaging is a candidate outcome measure for
unimpaired (CU) individuals > 50 years in the Mayo C
assessments, MR scans and 11C Pittsburgh compound
stratified participants by Aβ PET scan into 1) low Aβ,
(threshold=22 centiloid) Aβ, 3) low-suprathreshold A
months in tau PET signal in 4 regions – entorhinal, inf
Few 50-65 yo participants had suprathreshold Aβ leve
Aβ levels were distributed across the full range. Mean
compared to low Aβ. The high Aβ group had significa
groups only in the entorhinal ROI. Tau accumulation
suprathreshold Aβ groups in all regions were very low
these two Aβ groups. Tau accumulation rates in inferi
were greater than in the other Aβ groups. Rate of ento
was attenuated. Sample size estimates (25% reduction
subthreshold Aβ and low-suprathreshold Aβ groups w
high Aβ group were 6X smaller.
Suprathreshold Aβ and substantial acceleration of tau
evolve. The use of changes in tau signal as an outcom
feasible only in older individuals with high Aβ, repres
suprathreshold Aβ.

Keywords: Amyloid PET, tau PET, clinical trials, nor

49

nitively unimpaired persons with

au1, Michelle Mielke1, Val Lowe1, Sabrina
Ronald Petersen1, Cliff Jack1

r clinical trials for AD. We studied cognitively
Clinic Study of Aging who had serial cognitive
d B (Aβ) and 18F-AV1451 (tau) PET scans. We
, 2) above-background-but-still-subthreshold
Aβ and 4) high Aβ. We examined change over ~15
ferior temporal, lateral parietal and an AD meta-ROI.
els, and none had high Aβ levels. In 65-85 yos, index
n baseline tau signal was elevated in Aβ ranges
antly higher tau signal compared to the other Aβ
rates (Figure) in the subthreshold Aβ and low-
w with no differences in tau accumulation between
ior temporal and AD meta-ROI in the high Aβ group
orhinal cortex tau accumulation in the high Aβ group
n in tau accumulation rate, 80% power) for
were in the multi-thousands, while estimates for the
accumulation are related, but the latter takes years to
me measure in clinical trials of CU persons becomes
senting about half of CU persons with nominally

rmal cognition, longitudinal

96

Pontecorvo, Michael

Defining a tau positive Flortaucipir PE
neuropathology

Michael Pontecorvo1, Adam Fleisher1, Michael
Galante1, Edwin Lu1, Sudeepti Southekal1, Mark

1Avid Radiopharmaceuticals, Philadelphia, PA, US

Objective: To evaluate characteristics of the flortauci
to Braak NFT staging at autopsy.
Methods: 83 participants who underwent flortaucipir
status at autopsy (Figure 1). Flortaucipir images were
2 pivotal studies as consistent with AD (moderate: po
signal extended to parietal lobe, or frontal + parietal/te
uptake/restricted to anterior temporal or frontal lobes)
(MUBADA) and “early tau” (Eτ) VOIs. SUVrs ≥ me
positive. Groupwise average z-score surface maps we
Results: Moderate/advanced visual interpretation was
positive amyloid status and high ADNC, with both stu
for both sensitivity and specificity in > 3/5 readers). M
89.1%/86.1% and 89.4%/80.0% for B3 NFT and 95.1
Studies 1 and 2, respectively. Visual reads of the anter
accuracy for detecting B3 or B2 level NFT. MUBADA
than visual interpretation (Figure 2A) for B3 NFT. Al
appear to detect B2 NFT, 12/15 B2 NFT cases (includ
(Figure 2B). Thus, an Et VOI, potentially in combinat
identify subjects with intermediate stage tauopathy. R
signal as a function of NFT stage (Figure 3).
Conclusions: In two studies, moderate to advanced fl
ADNC pathology. Detection of earlier NFT stages ma

49

ET signal relative to AD

Devous1, Ming Lu1, Vikas Kotari1, Nicholas
k Mintun1

ipir PET signal that could define tau positivity relative

PET were evaluated for NFT stage and amyloid
visually interpreted by 10 imaging physicians across
osterior lateral temporal/occipital signal; or advanced:
emporal) or not consistent (Not AD: no
). Quantitative analyses used weighted neocortical
ean+2.5*SD of young controls were considered
ere generated regionally and Freesurfer vertex-wise.
s associated with B3 (Braak V/VI) NFT scores,
udies meeting the primary endpoint (95% LCL>0.50
Majority read sensitivity/specificity were
1%/82.9% and 95.1%/75.6% for high ADNC in
rior and medial temporal regions did not improve
A SUVr was more specific (100%) but less sensitive
lthough MUBADA and visual interpretation did not
ding 10/11 Braak IV cases) had elevated Et SUVr,
tion with MUBADA or visual reads, might help
Regional and vertex-wise analyses revealed flortaucipir

lortaucipir visual read was associated with B3/high
ay require quantitative methods.

97

49

98

Keywords: Tau, Flortaucipir, Braak stage, Positive Sc
49

can
99

KEYNOTE LECTURE

Tsai, Li-Huei

Leveraging brain rhythms as a therap
disease

Li-Huei Tsai

Picower Institute for Learning and Memory, Departm
Institute of Technology, Cambridge, MA, US
Rhythmic neural activity in the gamma range (30-80 H
function and has been shown to be disrupted in severa
disease (AD). Impaired gamma oscillations have also
before the onset of Aβ accumulation and major cognit
network oscillations at specific frequencies can be ind
Recently, we applied this approach, which we term G
using a light programmed to flicker at 40 Hz to induce
model mice. We found a profound reduction in amylo
that appears to involve the concerted actions of many
to reduce the production and enhance clearance of Aβ
amyloid plaque and phosphorylated Tau pathology in
transgenic mice, respectively, and improved learning
and powerful non-invasive approach to combat AD re
testing GENUS in human subjects to determine it’s ut

50

peutic intervention for Alzheimer’s

ment of Brain and Cognitive Sciences, Massachusetts
Hz) is modulated during various aspects of cognitive
al neurological conditions, including Alzheimer's
been reported in several AD mouse models, even
tive impairment. It is well established that local
duced in cortical areas using sensory stimuli.
Gamma ENtrainment Using Sensory stimuli (GENUS),
e gamma oscillations in the visual cortex of AD
oid load in visual cortex after 1 hr of visual GENUS
different cell types, including neurons and microglia
β, respectively. Chronic exposure to GENUS reduced
multiple brain regions in 5XFAD and P301S
and memory. Therefore, GENUS represents a novel
elated pathology and symptoms. We are currently
tility in tackling human neurological disorder.

00

Friday, January 17, 2020 - 2:00pm - 2:45pm

SESSION VIII: Clinical I

Friday, Janu

2:00 PM SESSION VIII:
CLINICAL III

Glucose metabolism reflects local atrophy
2:00 PM tau pathology at symptomatic stages of

Alzheimer's disease

Plasma FLT1 predicts amyloid-β related
2:15 PM cognitive decline in cognitively normal old

adults

2:30 PM Reducing sample sizes to detect longitudin
amyloid accumulation

2:45 PM Discussion

50